SCHEMBL25821003

SCHEMBL25821003

COC(=O)c1ccc(-c2ccnc(Cl)n2)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
KDM6B O15054 1/20 0.46
KDM5C P41229 1/20 0.46
KDM4C Q9H3R0 1/20 0.46
KDM2A Q9Y2K7 1/20 0.46
KDM3A Q9Y4C1 1/20 0.46
ALOX15 P16050 2/20 0.44
HTT P42858 1/20 0.44
SLC2A1 P11166 1/20 0.43
ALDH1A1 P00352 2/20 0.42
EIF2AK2 P19525 1/20 0.42
JMJD6 Q6NYC1 1/20 0.41
DYRK1A Q13627 1/20 0.41
ALPL P05186 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
CYP46A1 Q9Y6A2 1/20 0.40
CCNT1 O60563 1/20 0.39
CDK9 P50750 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
ABL1 P00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22097649 0.86 KMO (0.48) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL14059423 0.85 KDM4E (0.50) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL15921007 0.83 KDM4C (0.50) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL14058999 0.82 ATR (0.43) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL25820837 0.82 VCAM1 (0.48) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL16277261 0.80 CYP46A1 (0.60) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL15907818 0.79 KDM4E (0.50) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL17384817 0.77 EGFR (0.49) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL19103253 0.77 EGFR (0.49) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL14886606 0.77 ALOX15 (0.50) KDM4EKDM6BKDM5CKDM4CKDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203059-A1 MACROCYCLIC JAK INHIBITOR AND USES THEREOF BIOPOLAR HONGYE (NANTONG) PHARMACEUTICAL CO. LTD. (CN) 2023-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203059-A1 MACROCYCLIC JAK INHIBITOR AND USES THEREOF JAK3, JAK2, JAK1 KDM4E 1871/4885KDM6B 2718/4885KDM5C 1565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.